Harrow Health, Inc.
|Company Name||Harrow Health, Inc.|
On February 22, 2023, Bonitas Research published a report alleging, among other things, that Harrow had concealed a U.S. Department of Justice investigation into its sales practices and that it had engaged in suspect transactions with former subsidiaries. Moreover, Harrow did not disclose that it had received a warning letter from the U.S. Food and Drug Administration for making false and misleading marketing claims, but months later, the Company issued a nationwide recall.
On this news, Harrow’s stock price fell $0.54, or 3.2%, to close at $16.42 on February 22, 2023, thereby injuring investors.
Submit Your Information
If you suffered a loss on your Harrow Health, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.